Follow-up/Surveillance
Recommendation 6.1
➤ For patients on active cancer-directed therapy outside a clinical trial,
imaging to assess first response should be offered at 2 to 3 months
from the initiation of therapy. Computed tomography scans with
contrast are the preferred modality. Thereafter, clinical assessment,
conducted frequently during visits for cancer-directed therapy, should
supplant imaging assessment. The routine use of positron emission
tomography scans for the management of patients with pancreatic
cancer is not recommended. CA19-9 is not considered an optimal
substitute for imaging for the assessment of treatment response
(Strong recommendation; IC-B-L).
Recommendation 6.2
➤ No data exist on the duration of cancer-directed therapy. An ongoing
discussion of goals of care and assessment of treatment response and
tolerability should guide decisions to continue or to hold or terminate
cancer-directed therapy (Strong recommendation; IC-B-L).
Follow-up
